The aim of this study was to assess whether there is an association between changes in the heart rate and blood pressure after dipyridamole stress and abnormal scan findings detected with gated technetium-99m methoxy isobutylisonitrile (99mTc-MIBI) myocardial perfusion imaging (MPI). A total of 200 consecutive patients with known or suspected coronary artery disease underwent MPI using a 2 days stress/rest protocol. Heart rate (HR), blood pressure and electrocardiogram were monitored during the stress study. Dipyridamole-induced increase in HR ratio (peak HR/baseline HR) of more than 1.20 and decrease in systolic blood pressure (SBP) of 10 mmHg or more were defined as a normal response. Low ejection fraction (EF) was defined as EF less than 45%. Semi-quantitative measures used include summed stress score (SSS), summed difference score (SDS), end systolic volume (ESV) and left ventricular ejection fraction (LVEF). Chi-square-and regression analysis was used to assess associations between the various hemodynamic parameters and MPI abnormalities. Our results showed that 75% of patients had abnormal scans. Statistically significant associations were observed between each of the following factors and abnormal scan findings: abnormal SBP response to dipyridamole (P=0.011), increased SSS (P=0.040) and low LVEF (P=0.012). A significant association was also observed between decreased HR response and low LVEF (P=0.012). In conclusion, this study demonstrated that an abnormal hemodynamic response during dipyridamole stress test was associated with abnormal myocardial perfusion imaging scan findings, low LVEF and SSS.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1967/s002449910096 | DOI Listing |
Cardiovasc Pathol
January 2025
Department of Anatomical Sciences, St. George's University, School of Medicine, West Indies, Grenada; Department of Pathology, St. George's University, School of Medicine, West Indies, Grenada; Department of Clinical Anatomy, Mayo Clinic, Rochester, Minnesota, USA; Nicolaus Copernicus Superior School, College of Medical Sciences, Olsztyn, Poland. Electronic address:
Vascular occlusive diseases remain a major health burden worldwide, necessitating a deeper understanding of the adaptive responses that mitigate their impact. Arteriogenesis, the growth and remodeling of collateral vessels in response to arterial occlusion, is a vital defense mechanism that counteracts fluid shear stress-induced vascular stenosis or occlusion. While physical factors driving arteriogenesis have been extensively studied, the specific cellular mediators involved are poorly understood.
View Article and Find Full Text PDFInt J Nanomedicine
December 2024
Laboratory of Chemical, Galenic and Pharmacological Development of Medicines (LR12ES09), Faculty of Pharmacy of Monastir, University of Monastir, Monastir, Tunisia.
Background: Phosphodiesterase-4 is an enzyme that regulates immune responses and contributes to the development of psoriasis. Dipyridamole and roflumilast function as phosphodiesterase-4 inhibitors, reducing pro-inflammatory cytokine expression. The aim was to evaluate the anti-psoriatic effect of the topical administration of dipyridamole and roflumilast nanoemulgel combination on imiquimod-induced psoriasiform skin inflammation in rats.
View Article and Find Full Text PDFTheranostics
December 2024
Department of Geriatric Respiratory and Critical Care Medicine, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
: Ferroptosis in lung epithelium and endothelium contributes to the pathogenesis of acute respiratory distress syndrome (ARDS), a critical and often fatal condition marked by acute inflammation and elevated pulmonary vascular permeability. Despite this, there are currently no FDA-approved therapeutics specifically targeting ferroptosis for ARDS management. : A screening of 259 FDA-approved drugs was conducted to identify an effective ferroptosis inhibitor in pulmonary epithelial and endothelial cells.
View Article and Find Full Text PDFJ Leukoc Biol
December 2024
Division of Infectious Diseases, University of Pittsburgh School of Medicine, 818 Scaife Hall, 3550 Terrace Street, Pittsburgh, PA 15261, USA.
Twelve weeks of dipyridamole increased extracellular adenosine levels and decreased T cell activation in people with human immunodeficiency virus (HIV). In this analysis, we investigated the effect of dipyridamole on HIV-specific T cell responses. We compared changes in Gag- and Env-specific T cell responses using intracellular cytokine staining, following 12 wk of dipyridamole treatment vs placebo.
View Article and Find Full Text PDFJ Control Release
November 2024
Zhejiang Key Laboratory of Smart Biomaterials and College of Chemical and Biological Engineering, Zhejiang University, Hangzhou 310058, China; ZJU-Hangzhou Global Scientific and Technological Innovation Center, Hangzhou 311215, China; Key Laboratory of Biomass Chemical Engineering of the Ministry of Education, College of Chemical and Biological Engineering, Hangzhou, Zhejiang University, Hangzhou 310058, China. Electronic address:
In the realm of combined cancer immunotherapy, the strategic combination of therapeutics targeting both cancer cells and macrophages holds immense potential. However, the major challenges remain on how to achieve facile spatiotemporal delivery of these therapies, allowing ease of manipulation and ensuring differential drug release for enhanced synergistic therapeutic effects. In the present study, we introduced a tumor microenvironment (TME)-adapted hydrogel with the phenylboronic acid-modified dipyridamole prodrug (DIPP) as a crosslinker.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!